ISPO

Which dosing scheme is suitable for the taxanes? An in vitro model

UA Sanli,MD, R Uslu,MD, B Karabulut,MD, VC Sezgin,MD, G Saydam,MD, SB Omay,MD, PhD, F Buyukkececi, MD,E Goker, MD

Department of Hematology-Oncology Ege University Medical School, Bornova-Izmir, Izmir Turkey

The discovery and development of the taxane class of antitumor compounds represent significant advances in the treatment of patients with a variety of malignancies. These drugs are effectively used in the treatment of breast cancer. In this study we evaluated the efficacy of fractionated usage of both paclitaxel and docetaxel as a single agent in the breast cancer cell line MCF-7. It has been shown that the cytotoxic effect of paclitaxel was increased when the divided IC50 concentrations were used sequentially and in contrast to paclitaxel, cytotoxic effect of docetaxel was decreased with the same schema and the single dose of IC50 concentration was optimal. The cause of the difference between the cytotoxic effects of two agents with this schedule is obscure. Demonstrating mechanisms, which are responsible for these differences, will be important for more rational use of taxoids and to provide basis for the following clinical trials.

KEY WORDS: breast cancer, docetaxel, paclitaxel, cytotoxicity.

For more information, contact omay@med.ege.edu.tr

Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Paris, France; February 9 - 12, 2002; in the section on Novel Therapies, Part 1.

http://www.cancerprev.org/Journal/Issues/26/101/1195/4614